Fagron publishes its Annual Report 2025

06 Mar 2026 07:00 CET

Issuer

FAGRON S.A.

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET

Fagron publishes its Annual Report 2025

Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron's annual financial results for the financial year 2025 on February 12, 2026.

The Annual Report is available on Fagron's website in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated financial statements, as well as the sustainability report, for the financial year 2025.

The Annual Report will be presented to the Annual General Meeting of Shareholders, scheduled to be held on May 11, 2026.

Financial calendar
9 April 2026                         Trading update first quarter 2026
11 May 2026                        Annual General Meeting 2026
30 July 2026                        Half year results 2026
8 October 2026 Trading update third quarter 2026

Results and trading updates are published at 7.00 AM CET.

Further information
Ignacio Artola
Global Head of Investor Relations
Tel. +34 670385795
ignacio.artola@fagron.com

About Fagron
Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 38 countries around the world.

The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office located in Rotterdam.

Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment